Adult inpatient VTE prevention policy
Case reference FOI2026/05902
Received 12 October 2026
Published 11 November 2026
Request
This request forms part of a study describing variation in VTE prevention policy across NHS acute trusts. No patient identifiable information is requested.
1. VTE PREVENTION POLICY
1.1 A copy of the trust's current VTE prevention policy for adult inpatients, including all appendices. Where the policy is published, a direct link to the current version is sufficient.
Questions 2 to 4 concern matters that may already be addressed in the documents requested above. Where the answer is clearly stated in a document you supply, please feel free to refer to the document rather than repeating the answer.
2. SPECIALITY-SPECIFIC PROVISION
2.1 Whether the policy at 1.1 contains speciality-specific guidance, and if so for which specialities.
2.2 Where VTE prevention for any speciality is governed by a separate document rather than the main policy, a copy of that document.
2.3 Confirmation of whether the trust is designated as a Major Trauma Centre, a Trauma Unit, or neither, and whether there is any trauma-specific guidance.
3. RISK ASSESSMENT
3.1 The name of the risk assessment model in use for adult inpatients, for example the Department of Health national tool, Padua, IMPROVE, Caprini, or a locally developed or modified tool.
3.2 A copy of the risk assessment proforma or form, if it is not reproduced within the policy supplied at 1.1.
3.3 Whether a single model applies trust wide, or whether different models are used for different specialities or admission routes. If the latter, please state which model applies to which group.
3.4 How risk assessment is recorded: on paper, electronically, or a combination.
4. PROPHYLAXIS
4.1 The pharmacological agents recommended as first line for adult inpatients, with doses.
4.2 Whether weight-based or weight-banded dosing is specified, and the thresholds used.
4.3 The recommended duration of prophylaxis, and any criteria for extended prophylaxis after discharge.
4.4 The mechanical prophylaxis modalities recommended, for example anti-embolism stockings or intermittent pneumatic compression, and the circumstances in which each is indicated.
5. AUDIT AND COMPLIANCE
5.1 Copies of, or extracts from, any local audit of thromboprophylaxis prescribing, policy compliance, or risk assessment completion undertaken in the last 24 months. Board papers, quality account extracts or thrombosis committee reports are acceptable.
5.2 The number of cases of hospital-acquired thrombosis (HAT) recorded by the trust in each of the last two full financial years.
5.3 Whether the trust undertakes root cause analysis of HAT cases, and the criteria determining which cases are investigated.
Response
This request forms part of a study describing variation in VTE prevention policy across NHS acute trusts. No patient identifiable information is requested.
1. VTE PREVENTION POLICY
1.1 A copy of the trust's current VTE prevention policy for adult inpatients, including all appendices. Where the policy is published, a direct link to the current version is sufficient.
The Following -Venous Thromboembolism (VTE) Prevention and Management Policy (excluding pregnancy and the puerperium) is published on the intranet site-Anticoagulation & Thrombosis
Venous Thromboembolism Prevention and Management Policy
GS85-Reducing the Risk Of Venous Thromboembolism (VTE) During and After Guideline is published on the Intranet Site-Anticoagulation & Thrombosis
https://ouhnhsuk.sharepoint.com/sites/maternity/Lists/Maternity%20Guidelines/DispForm.aspx?ID=160
Questions 2 to 4 concern matters that may already be addressed in the documents requested above. Where the answer is clearly stated in a document you supply, please feel free to refer to the document rather than repeating the answer.
2. SPECIALITY-SPECIFIC PROVISION
2.1 Whether the policy at 1.1 contains speciality-specific guidance, and if so for which specialities.
The above document states " This document summarises the Trust`s approach to the risk assessment and prevention of VTE for inpatients 16 years or more and the investigation and treatment of VTE for patient 18 years or more . For patients who
Are pregnant or up to 6 wks post-partum, please refer to the the VTE Reducing the Risk of Venous Thromboembolism (VTE) During and after pregnancey and investigation guideline and acute management of VTE in pregnancy and puerperium guideline.
For those under the age of 16 please refer to the Children`s VTE Prevention Operating Procedure. OUH Childrens Venous Thrombosis prevention SOP v4_14Jan2026.pdf
2.2 Where VTE prevention for any speciality is governed by a separate document rather than the main policy, a copy of that document.
See above
2.3 Confirmation of whether the trust is designated as a Major Trauma Centre, a Trauma Unit, or neither, and whether there is any trauma-specific guidance.
Yes - designated as a Major Trauma Centre.
No - Specific Trauma Specific Guidance
3. RISK ASSESSMENT
3.1 The name of the risk assessment model in use for adult inpatients, for example the Department of Health national tool, Padua, IMPROVE, Caprini, or a locally developed or modified tool.
The VTE Risk Assessment tool is based on the national tool and complies with NICE guidance
3.2 A copy of the risk assessment proforma or form, if it is not reproduced within the policy supplied at 1.1.
The Trust VTE Risk Assessment tool is electronic- See attached for down time use
3.3 Whether a single model applies trust wide, or whether different models are used for different specialities or admission routes. If the latter, please state which model applies to which group.
1x models- 1 for 16yrs and above
1x model-Maternity Specific VTE RA Tool
3.4 How risk assessment is recorded: on paper, electronically, or a combination.
Electronic
4. PROPHYLAXIS
4.1 The pharmacological agents recommended as first line for adult inpatients, with doses.
Enoxaparin (LMWH)
|
Weight (kg) |
Dose |
|
Less than 50 |
20mg once daily |
|
50-100 |
40mg once daily |
|
101-150 |
60mg once daily |
|
More than 150 |
40mg twice daily |
4.2 Whether weight-based or weight-banded dosing is specified, and the thresholds used.
Yes- See above
4.3 The recommended duration of prophylaxis, and any criteria for extended prophylaxis after discharge.
|
Surgery |
Thromboprophylaxis |
|
Elective knee replacement |
Starting 6 hours post operatively and to complete a total of 14 days: - Rivaroxaban 10mg once daily - LMWH (see separate MIL for dosing information) - Aspirin 150mg once daily + omeprazole* 20mg once daily |
|
Elective hip replacement |
Starting 6 hours post operatively - Rivaroxaban 10mg once daily to complete a total of 35 days - LMWH to complete a total of 28-35 days (see separate MIL for dosing information). - LMWH for 10 days, followed aspirin 150mg once daily + omeprazole* 20mg once daily for a further 28 days |
|
Fragility fracture of the pelvis, hip or proximal femur, including arthroplasty for this indication |
Prophylactic enoxaparin for 28 days post- operatively and mechanical thromboprophylaxis until discharge |
|
Arthroscopic knee surgery, if total anaesthetic time greater than 90 minutes (or risk of thrombosis outweighs risk of bleeding). Other knee surgery (for example, osteotomy or fracture surgery) with total anaesthetic time greater than 90 minutes |
Prophylactic enoxaparin for 14 days post operatively and mechanical thromboprophylaxis until discharge |
|
Lower limb immobilisation |
See lower limb immobilisation MIL for patients eligible for prophylactic enoxaparin |
|
Major abdominal cancer surgery |
Prophylactic enoxaparin for 28 days post operatively and mechanical thromboprophylaxis until discharge |
|
High risk patients with a previous VTE may need extended thromboprophylaxis after lower risk procedures; or a longer duration of extended thromboprophylaxis after a high risk procedure |
Please contact haematology for advice (either the Coag SpR on bleep 5529 during normal working hours, or the Haem SpR via switch out of hours) |
4.4 The mechanical prophylaxis modalities recommended, for example anti-embolism stockings or intermittent pneumatic compression, and the circumstances in which each is indicated.
Embolism Stocking removed from Clinical Practice- 1/10/26- Intermittent Pneumatic compression-See attached indication
5. AUDIT AND COMPLIANCE
5.1 Copies of, or extracts from, any local audit of thromboprophylaxis prescribing, policy compliance, or risk assessment completion undertaken in the last 24 months. Board papers, quality account extracts or thrombosis committee reports are acceptable.
See attached Trust Wide Audit of Appropriate Thromboprophylaxis
5.2 The number of cases of hospital-acquired thrombosis (HAT) recorded by the trust in each of the last two full financial years.
2024-2025-Not Potentially Preventable-283
Potentially Preventable-32 (Minor-20/Moderate-12)
2025-2026-Not Potentially Preventable-259
Potentially Preventable-37 (Minor 18/Moderate-19)
5.3 Whether the trust undertakes root cause analysis of HAT cases, and the criteria determining which cases are investigated.
Yes-Robust Hospital Associated Thrombosis Process in place- 100% of Identified Deep Vein Thrombosis and Pulmonary Embolism are investigated.
Documents
- Medical In-Patients On The Ward (age 16y and older) Intermittent Pneumatic Compression (IPC) Use.pdf (73.7 KB)
- OUH VTE Assessment Downtime Form - Medical Patient (1).pdf (597.7 KB)
- OUH VTE Assessment Downtime Form - Surgical Patient.pdf (548.1 KB)
- Surgical and Critical Care In-Patients (age 16 y and older) Intermittent Pneumatic Compression (IPC) Use.pdf (87.2 KB)
- Trust Wide Audit-Divisional Report-December 25-VTE-Final.pdf (440.7 KB)
This is Oxford University Hospitals NHS Foundation Trust's response to a freedom of information (FOI) or environmental information regulations (EIR) request.
You can browse our other responses or make a new FOI request.